Data protection Impressum

Life sciences

Geneva-based EarlySight has raised an additional CHF 3.1 million, bringing its seed financing round to CHF 6.1 million, to launch its next-generation product and advance U.S. approval.

Retinal imaging specialist EarlySight raises CHF 3.1 million to accelerate global growth

10 September 2025

A new automated platform developed by cellvie and CSEM streamlines mitochondria isolation, advancing therapeutic transplantation for ischemia-reperfusion injury.

CSEM and cellvie automate mitochondria isolation for clinical use

9 September 2025

Bern-based medtech Rhovica Neuroimaging has secured CHF 2.3 million to accelerate development of its SoNav system for safer emergency neurosurgery.

Rhovica raises CHF 2.3 million to advance bedside neurosurgery navigation

2 September 2025

A study by CHUV and UNIGE published in Nature Neuroscience shows that virtual reality scenarios can activate the human immune system in the absence of real pathogens.

CHUV and UNIGE study shows virtual reality can trigger an immune response

20 August 2025

Pilatus Biosciences launches first-in-human trial in collaboration with Roche

20 August 2025

Researchers from HUG and UNIGE have developed patient-derived lung cancer “mini-tumors” to rapidly identify the most effective personalized treatments.

Geneva team develops lung cancer “mini-tumors” to accelerate personalized treatments

13 August 2025

Researchers at the University of Geneva have uncovered that astrocytes in the brain’s cortex originate from two distinct types of progenitors, a finding that could reshape therapeutic strategies for neurological disorders.

University of Geneva researchers uncover two distinct origins of key brain cells

11 August 2025

Two start-ups from Western Switzerland’s Health Valley, AzureCell Therapies and Myriad Optics, have each been awarded CHF 150,000 through the Gebert Rüf Stiftung’s Innobooster programme, which supports high-potential projects emerging from Swiss universities.

AzureCell Therapies and Myriad Optics awarded by Gebert Rüf Stiftung’s Innobooster programme

11 August 2025

Biopôle has evolved its Start Up Fund into a 24 month scheme combining non dilutive capital, investor training and growth support.

Biopôle launches enhanced Investment Programme to boost life sciences start‑ups

6 August 2025

Oculis expands its loan facility with BlackRock to CHF 100 million, extending its financial runway and supporting late-stage clinical trials.

Oculis secures up to CHF 100 million in expanded loan facility with BlackRock

5 August 2025

1 2 3 4 5 … 44